Skip to content
Demo
Creator Hubs›Crown Bioscience

Crown Bioscience

Crown Bioscience logo

News, updates, and expert insights from Crown Bioscience.

Advance translational oncology with Crown Bioscience, a full-service CRO delivering comprehensive preclinical and oncology CRO services worldwide. Follow this channel for the latest from Crown Bioscience: product news, expert perspectives, and updates from the team.

5 episodesVisit website ↗
Channel Brief·Crown Bioscience · 5 episodes
Updated Sep 30, 2026

Precision Preclinical Models Drive Oncology Drug Discovery Forward

Crown Bioscience argues that cancer therapies succeed when preclinical models match the therapy being tested, not the reverse. The channel builds this case through specific model innovations and emerging technologies.

Crown Bioscience's core argument is that oncology drug development requires fitting the preclinical model to the therapy, including its delivery route, surgical demands, and target organ. This inversion of the usual logic is supported across five episodes that detail orthotopic brain tumor implantation, patient-derived xenografts from post-treatment tumors, organoid technology, resistance mechanisms, and AI-driven compound identification as interconnected solutions to the same problem: making preclinical prediction clinically relevant.

Drawn from Crown Bioscience's San Diego site fits the tum… and 4 more →

“A preclinical model should fit the therapy being tested, including its delivery route, the surgery it needs and the organ it targets.”

Crown Bioscience's San Diego site

By the numbers

300+

new FDA-approved cancer therapies in last two decades

$230B+

projected global pharmaceutical R&D spending by 2026

~50%

reduction in drug development timelines achievable with AI

What the channel argues

InsightOrthotopic brain tumor implantation enables tumor growth in the organ where it naturally occurs, supporting clinically relevant therapy assessment.→
InsightPatient-derived xenografts from post-treatment tumors better reflect progressed disease, helping study therapies for advanced cancer patients.→
InsightOrganoids mirror human biology more closely than traditional 2D models or animal systems, predicting patient-specific drug responses.→
DataCancer cells evolve to evade treatment, with over 300 FDA-approved therapies facing resistance as a critical ongoing challenge.→
DataAI can slash drug development timelines by nearly half while improving accuracy in identifying promising compounds.→

What you'll learn

•Why testing a brain tumor therapy in the brain, not under the skin, changes what developers learn about efficacy and delivery.
•How organoid technology shifts oncology from predicting average responses to anticipating patient-specific outcomes.
•That resistance is not a flaw in individual therapies but a fundamental cell adaptation problem requiring combination strategies and deeper biology.
•How AI-enhanced approaches and multi-omics help identify resistance pathways faster, reducing development cycles and R&D costs.
•Why the tumor microenvironment and immune cell exhaustion are now central to designing immuno-oncology combinations that work.

What to do about it

→Evaluate whether your preclinical partner can build models that match your therapy's delivery route, target organ, and surgical requirements, not generic tumor lines.
→Incorporate organoid testing and biomarker analysis alongside in vivo models to predict patient-specific responses before clinical trials.
→Design resistance studies into early development using CRISPR, multi-omics, and AI-driven models to anticipate cell adaptation and plan combination strategies.

Questions this channel answers

Q

Why does it matter where a tumor is implanted in a preclinical model?

Orthotopic implantation in the natural organ allows the tumor to grow and receive therapy in the same setting as patients, making efficacy and delivery assessment clinically relevant rather than convenient.

Crown Bioscience's San Diego site fits the tumor model t… →
Q

How do cancer cells develop resistance to even advanced therapies?

Cancer cells evolve and adapt to evade treatment over time. New tools like CRISPR, multi-omics, and AI-enhanced models help researchers understand the pathways driving resistance so combination therapies and personalized approaches can be designed.

Inside Oncology Drug Development: Overcoming Resistance … →
Q

What advantage do organoids offer over traditional animal models?

Organoids are miniature 3D lab-grown tissues that mirror human biology more closely than 2D models or animal systems, allowing researchers to predict patient-specific drug responses more accurately.

Growing the Future of Cancer Research: Inside the Promis… →
Q

How does AI speed up drug discovery?

AI can cut drug development timelines by nearly half while improving accuracy in identifying promising compounds, helping biotech companies offset rising R&D costs and long development cycles.

Exploring Artificial Intelligence in Drug Discovery →
Q

Why are combination therapies critical in immuno-oncology?

Combination therapies are needed to overcome immune resistance and address challenges posed by the tumor microenvironment and immune cell exhaustion, expanding treatment possibilities beyond single-agent approaches.

Shaping the Future of Cancer Care Through Immuno-Oncolog… →
Topics:Orthotopic tumor models and brain implantationPatient-derived xenografts and resistanceOrganoid technology and 3D tissue systemsImmuno-oncology and combination therapiesAI and computational drug discovery
Themes:Model-therapy fit as the foundation of clinical translationEmerging technologies revealing resistance and personalized responsePrecision preclinical design reduces failed trials and R&D waste

Industry context

Cancer therapeutics markets are projected to exceed $500 billion by 2035, while preclinical models are evolving from traditional cell-line xenografts to sophisticated patient-derived approaches for improved efficacy and toxicity assessment.

Want a show like this for your brand?

MarketScale produces and distributes branded shows like Crown Bioscience for B2B companies.

Book a Demo →